TG Therapeutics (NASDAQ:TGTX) Shares Down 5.9% – What’s Next?

TG Therapeutics, Inc. (NASDAQ:TGTX)’s share price was down 5.9% on Monday . The stock traded as low as $30.00 and last traded at $30.3450. Approximately 1,156,140 shares traded hands during trading, a decline of 51% from the average daily volume of 2,346,815 shares. The stock had previously closed at $32.24.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TGTX. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. HC Wainwright started coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 price target on the stock. Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.25.

TG Therapeutics Price Performance

The stock’s 50 day simple moving average is $33.91 and its 200-day simple moving average is $34.64. The firm has a market cap of $4.81 billion, a price-to-earnings ratio of 81.92 and a beta of 1.95. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $2.19. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm had revenue of $161.71 million for the quarter, compared to the consensus estimate of $152.12 million. During the same period in the prior year, the firm earned $0.02 EPS. The firm’s revenue was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the transaction, the director directly owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 10.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Crossmark Global Holdings Inc. acquired a new stake in TG Therapeutics during the 1st quarter worth about $226,000. Xponance Inc. boosted its stake in shares of TG Therapeutics by 5.3% in the first quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 543 shares during the last quarter. CWM LLC boosted its stake in shares of TG Therapeutics by 16.2% in the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 290 shares during the last quarter. Edgestream Partners L.P. grew its holdings in TG Therapeutics by 21.4% during the first quarter. Edgestream Partners L.P. now owns 65,249 shares of the biopharmaceutical company’s stock worth $2,573,000 after acquiring an additional 11,511 shares during the period. Finally, Sigma Planning Corp purchased a new position in TG Therapeutics during the first quarter valued at approximately $1,252,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.